TY - JOUR T1 - Androgen Receptor and <em>PIM1</em> Expression in Tumor Tissue of Patients With Triple-negative Breast Cancer JF - Cancer Genomics - Proteomics JO - Cancer Genomics Proteomics SP - 147 LP - 156 DO - 10.21873/cgp.20249 VL - 18 IS - 2 AU - ALIKI NTZIFA AU - ARETI STRATI AU - GEORGIA-ANGELIKI KOLIOU AU - FLORA ZAGOURI AU - DIMITRIOS PECTASIDES AU - GEORGE PENTHEROUDAKIS AU - CHRISTOS CHRISTODOULOU AU - HELEN GOGAS AU - CHRISTINA MAGKOU AU - CONSTANTINA PETRAKI AU - PARIS KOSMIDIS AU - GERASIMOS ARAVANTINOS AU - VASSILIKI KOTOULA AU - GEORGE FOUNTZILAS AU - EVI LIANIDOU Y1 - 2021/03/01 UR - http://cgp.iiarjournals.org/content/18/2/147.abstract N2 - Background/Aim: Effective targeted therapies for triple-negative breast cancer (TNBC) are limited. In a subset of TNBC, androgen receptor (AR) plays an important role, while the human proviral integration site for Moloney murine leukemia virus-1 (PIM1) overexpression is also implicated. PIM1 kinases phosphorylate AR, thus regulating its transcriptional activity, regardless of the presence or not of androgens. We evaluated the expression of AR and PIM1 and their prognostic significance in TNBC. Materials and Methods: AR and PIM1 transcripts were quantified by quantitative reverse transcription polymerase chain reaction in formalin-fixed paraffin-embedded tumor from 141 patients with TNBC. Results: AR was expressed in 38.3%, PIM1 in 10.6%, while co-expression of AR and PIM1 was detected in 7/141 cases (5.0%). No prognostic significance of AR or PIM1 was reached for overall or disease-free survival. Conclusion: Co-expression of AR and PIM1 exists in only in a small percentage of patients with TNBC. The implications of this finding in the therapeutic management of patients with TNBC should be investigated in larger patient cohorts. ER -